Shares of Omeros Bounce Over $5.40 Following Mid-Day Comments from MLV's Zavoico

MLV analyst George Zavoico issued an intraday research note on Omeros Corp.

Monday afternoon. While the stock is still down about 3 percent for the session, the price bounced off an afternoon low around $5.38. The analyst highlighted the combination of clinical trial programs underway for OMS721 and OMS824 by year end and the commercial launch of OMS302 as making Omeros shares a "compelling investment opportunity that we think is undervalued at this time." Zavoico is expecting "Omeros to add to its cash reserves by the sale of newly issued stock or, preferably, by establishing a collaborative partnership agreement for at least one of its drug candidates" by the end of 2013. The MLV analyst maintains a Buy rating and $14 price target on shares of Omeros.